vTv Therapeutics (VTVT) Retained Earnings (2015 - 2026)

vTv Therapeutics has disclosed Retained Earnings across 12 years of filings, most recently posting -$302.6 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$302.6 million, up 0.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$302.6 million (up 0.74% YoY), and the FY2025 annual result was -$326.7 million, down 9.0% from the prior year.
• Retained Earnings came in at -$302.6 million for Q1 2026 at vTv Therapeutics, up from -$326.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$247.7 million in Q1 2022 to a low of -$326.7 million in Q4 2025.
• The 5-year median for Retained Earnings is -$286.1 million (2024), against an average of -$287.6 million.
• Across the five-year window, Retained Earnings rose 9.84% in 2022 and dropped 10.86% in 2023, its largest moves.
• vTv Therapeutics' Retained Earnings stood at -$265.5 million in 2022, then retreated by 5.84% to -$281.0 million in 2023, then decreased by 6.65% to -$299.7 million in 2024, then slipped by 9.0% to -$326.7 million in 2025, then advanced by 7.39% to -$302.6 million in 2026.
• The last three Retained Earnings figures came in at -$302.6 million (Q1 2026), -$326.7 million (Q4 2025), and -$319.6 million (Q3 2025), per Business Quant data.